EVALUATION OF THE EFFICACY OF REBAMIPIDE IN PATIENTS WITH NSAID-ASSOCIATED GASTROPATHY
Keywords:
Key words: NSAID-gastropathy, cytoprotectors, rebamipidAbstract
An increase in the incidence of NSAID-gastropathy is associated with the widespread use of NSAIDs (nonsteroidal anti-inflammatory drugs) in almost all areas of medicine. An important element of the prevention and treatment of NSAID-gastropathy is the use of drugs that have a cytoprotective effect on the gastric mucosa. The cytoprotector rebamipid has great therapeutic potential, confirmed in a variety of experimental and clinical studies. The use of rebamipid is justified both for conditionally healthy individuals if a short course of NSAID therapy is necessary, and for patients who need a long or lifelong intake of them, especially in the presence of risk factors for the development of NSAID-gastropathy.
References
. Галушко, Е. А. Распространенность ревматических заболеваний в России / Е. А. Галушко, Е. Л. Насонов // Альманах клинической медицины. — 2018. — № 1. — С. 32-39.
Ивашкин, В. Т. Клинические рекомендации РГА по диагностике и лечению эро¬зивно-язвенных поражений желудка и двенадцатиперстной кишки, вызванных нестероидными противовоспалительными препаратами / В. Т. Ивашкин [и др.] // РЖГГК. — 2014. — № 6. — С. 89-94.
Каратеев, А. Е. Рациональное использование нестероидных противовоспали¬тельных препаратов. Клинические рекомендации / А. Е. Каратеев [и др.] // Научно-практическая ревматология. — 2018. — Т. 56. — С. 1-29.
Российские клинические рекомендации. Ревматология / под ред. Е. Л. Насонова —
Arakawa, T. Rebamipide, novel prostaglandin-inducer accelerates healing and re¬duces relapse of acetic acid-induced rat gastric ulcer. Comparison with cimetidine / T. Arakawa [et al.] // Dig. Dis. Sci. — 1995. — Vol. 40. — P.
